Vimarsana
Biggest News Aggregation in the World

David Veitch News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from David Veitch. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In David Veitch Today - Breaking & Trending Today

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea - Vimarsana News

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea

Allschwil, Switzerland, May 16, 2024 Basilea Pharmaceutica Ltd, Allschwil , a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal...

Made in Cley, in Cley-next-the-Sea, celebrates 40th birthday - Vimarsana News

Made in Cley, in Cley-next-the-Sea, celebrates 40th birthday

Made in Cley was founded by four friends from Germany, Britain and the USA who met while working and studying in Germany.

Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indications - Vimarsana News

Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indications

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, April 04, 2024 Basilea Pharmaceutica Ltd, Allschwil , a commercial-stage biopharmaceutical company committed to meeting the...

FDA approves new antibiotic for several hard-to-treat infections - Vimarsana News

FDA approves new antibiotic for several hard-to-treat infections

BioPharma

Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea - Vimarsana News

Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea

Allschwil, Switzerland, March 11, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer Inc. in the Asia Pacific region and China exceeded the sales threshold triggering a USD 1.25 million milestone payment. David Veitch, Basilea’s

Source: yahoo.com